Phase IB Trial of LDE225 and Weekly Paclitaxel in Recurrent Platinum Resistant Ovarian Cancer
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 22 Sep 2017
At a glance
- Drugs Sonidegib (Primary) ; Paclitaxel
- Indications Ovarian cancer
- Focus Adverse reactions
- 18 Sep 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Dec 2017.
- 06 Feb 2017 Status changed from recruiting to active, no longer recruiting.
- 28 Sep 2016 Planned End Date changed from 1 Apr 2017 to 1 Apr 2018.